JP Morgan Initiates Coverage On Neurogene with Overweight Rating, Announces Price Target of $60

Benzinga Newsdesk www.benzinga.com Neutral 61.8%

Neg 0% Neu 61.8% Pos 0%

JP Morgan analyst Priyanka Grover initiates coverage on Neurogene (NASDAQ:NGNE) with a Overweight rating and announces Price Target of $60.